A recap of the top headlines from Contemporary OB/GYN in September 2026, spanning ACOG's respiratory vaccine guidance to the launch of the Missed & Dismissed podcast.
|Articles|January 26, 2022
Society for Maternal-Fetal Medicine Special Statement: COVID-19 research in pregnancy: progress and potential
The COVID-19 global pandemic has broad implications for obstetrical care and perinatal outcomes. As we approach the 2-year mark into an unprecedented international pandemic, this review presents the progress and opportunities for research related to COVID-19 and pregnancy.
Advertisement
Research is the basis for evidence-based clinical guidelines, and we aim to provide the structure and guidance for framing COVID-19erelated obstetrical research. This structure will pertain not only to this pandemic but future ones as well.
Advertisement
Related to this article
A recap of Contemporary OB/GYN's top FDA and regulatory news from September 2026.
Fezolinetant was linked to VMS and sleep improvements by week 4 in the real-world OPTION-VMS study, presented at the International Menopause Society World Congress.
Wen Shen, MD, highlights perimenopause as an important period for identifying health risks and supporting healthy aging beyond the menopausal transition.
A global consensus published in The Lancet has officially renamed polycystic ovary syndrome to polyendocrine metabolic ovarian syndrome, a change with broad implications for diagnosis, care, and cardiometabolic screening.
The Preeclampsia Foundation released 2 videos on postpartum recovery and long-term health after HDP.
AJOG research shows a cytokine storm could be detectable in maternal blood before the clinical onset of AFE.
CDC data show gestational hypertension rose 73% from 2016 to 2024, affecting 1 in 10 US mothers giving birth.
Advertisement
Advertisement
Trending on Contemporary OB/GYN
1
IMS: Fezolinetant's improvements in sleep quality, hot flashes as early as week 4
2
Wen Shen, MD, on recognizing perimenopause as a window for healthy aging
3
Top headlines in women's health from September 2026
4
A recap of top FDA & regulatory news from September 2026
5